However, published open‐label19 and real‐world experiences15, 17 with deutetrabenazine and other VMAT2 inhibitors indicate that this class of anti‐dopaminergic agents is well tolerated and may show efficacy in the treatment of tics associated with TS when appropriately dosed.17 The gene discussed is SLC18A2; the disease is Tics.